New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
09:36 EDTABX, TWTR, GILD, LVS, AAPLActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD ABX LVS TWTR
News For AAPL;GILD;ABX;LVS;TWTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>
July 21, 2015
16:30 EDTAAPLApple sees Q4 revenue $49B-$51B, consensus $51.05B
Sees Q4 gross margin 38.5%-39.5%.
16:30 EDTAAPLApple reports Q3 EPS $1.85, consensus $1.81
Reports Q3 revenue $49.6B, consensus $49.31B.
16:01 EDTAAPLOptions Update; July 21, 2015
iPath S&P 500 VIX Short-Term Futures down 13c to 16.20. Option volume leaders: AAPL BAC FB BAC MSFT NFLX AMD IBM CHK
15:56 EDTAAPLApple July weekly 131 straddle priced for 5.2% movement into Q3
15:02 EDTAAPLNotable companies reporting after market close
Subscribe for More Information
14:14 EDTAAPLEarnings Watch: Apple flat since last report with iPhone, Watch results in focus
Subscribe for More Information
14:12 EDTGILDGilead reports study of E/C/F/TAF met primary endpoint
Gilead Sciences announced detailed 48-week data from an open-label Phase 3 study evaluating its investigational once-daily single tablet regimen of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg, or E/C/F/TAF, among 1,436 virologically suppressed adult patients switching from tenofovir disoproxil fumarate-containing regimens. The study met its primary endpoint by demonstrating non-inferiority of E/C/F/TAF to the TDF-based regimens at Week 48. The study also demonstrated statistical superiority among patients with HIV-1 RNA levels less than 50 copies/mL at Week 48 and statistically significant improvements in bone and renal laboratory parameters. These data were presented in an oral session at the 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention in Vancouver, Canada. Among the 1,436 patients who were randomized in the study, virologic success rates at Week 48 were higher in patients taking E/C/F/TAF, 97% versus 93% for all TDF-based regimens; difference in percentages: 4.1%, 95% CI: 1.6% to 6.7%. The rates of virologic failure were similar between the two arms, with E/C/F/TAF, 1.0% and TDF-based regimen, 1.3%. General safety was similar between the two arms through 48 weeks of treatment, with similar percentages of patients in each group having any adverse events. Adverse events leading to treatment discontinuation were more common among patients treated with a TDF-based regimen.
13:43 EDTAAPLApple services restored after nearly 4-hour outage, CNBC reports
Subscribe for More Information
13:21 EDTAAPLApple July weekly 131 straddle priced for 4.7% movement into Q3
11:39 EDTAAPLApple experiencing issues with App Store, iTunes Store, CNBC reports
Subscribe for More Information
10:31 EDTABXOptions with increasing implied volatility
Options with increasing implied volatility: DUST JNUG LINE CHK CNX INSY ABX GG GDX NEM
10:05 EDTAAPLApple technical notes ahead of results
The stock has been trading in a range since February of this year that is bound by a low at $120 and a high at $133. There have been three touches at the range high since then and two tests at the low suggesting the bias is for a breakout. If the news is strongly bullish, notably around China sales and guidance, a breakout above $133 and the brief life high at $134.54 would be highly probable. Based on the height of the range the upside potential would be to $147 to $150. Without overhead resistance, price could continue to drift beyond that objective depending on the strength of the news. If the news is a bearish surprise, which very few expect, the low of the range would likely be tested for a third time. A breakdown below $120 would have the same range expectations as on the upside, with a downside target potential to $107 to $105 implied from the range height. Such a move would break the 10-month moving average at $122.16 which has been a good proxy for the uptrend that began off lows in August 2013. The last time this average was broken was during the downturn in price in late 2012 which then ended in August 2013.
09:35 EDTAAPLActive equity options trading on open
Active equity options trading on open: AAPL FB IBM TSLA BAC PVA NFLX
07:45 EDTAAPLSell PayPal amid mounting payments competition, Piper says
Shares of PayPal (PYPL) advanced over 5% yesterday in the stock's first day of trading following a split from eBay (EBAY), with the majority of research firms issuing optimistic notes on its prospects. This morning, however, analyst Gene Munster of Piper Jaffray recommends selling the share as competition grows in the digital payments space. BEARS: Munster started shares of PayPal with an Underweight rating, the firm's equivalent of a "Sell," saying increased competition could pressure the stock's multiple over the next 6-24 months. Google's (GOOG) Android Pay and Apple's (AAPL) Apple Pay will give consumers a "real alternative to PayPal" for the first time, Munster tells investors in his research note. In addition, interest in payments from Amazon.com (AMZN) and Facebook (FB) bring potential for more digital wallet offerings, the analyst notes. Munster set a $30 price target for PayPal. Of note, Evercore ISI also started coverage of PayPal shares yesterday with a Sell rating. BULLS: Wells Fargo initiated coverage of PayPal yesterday with an Outperform rating, saying the company's unique assets will enable it to maintain its leadership role in digital payments and benefit from the growth of e-commerce. Also upbeat was Robert W. Baird analyst Colin Sebastian, who contends that PayPal has the top pure play online payment system and is continuing to grow its share of the Internet payment market. PayPal should be able to innovate more effectively after its spin-off, added the analyst, who set a $45 price target on the shares. PRICE ACTION: Shares of PayPal are pointing toward further gains in their second day of standalone trading, with the stock up about 2.7% to $41.55 in pre-market trading.
07:38 EDTAAPLApple July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
07:00 EDTAAPLApple granted patent for 'fine tuning' input taps, AppleInsider reports
A patent granted to Apple by the USPTO involves a method of highly granular user interface manipulations by tapping on the side of an iPhone to "nudge" onscreen items with great precision, reported AppleInsider. Reference Link
06:46 EDTAAPLApple July weekly 132 straddle priced for 4.7% movement into Q3
Subscribe for More Information
06:23 EDTAAPLApple's iPhone 6s will cut 16GB version, M.I.C. Gadget reports
Apple's (AAPL) new iPhone 6s and 6s Plus will not come with a 16GB edition yet will have a 32GB edition with more capacity, M.I.C. Gadget reports, citing "some Foxconn (FXCNY) insiders." Reference Link
06:19 EDTAAPLSilicon Valley giants side with Samsung in battle with Apple, InsideSources says
Subscribe for More Information
05:34 EDTAAPLPayPal initiated with an Underweight at Piper Jaffray
Piper Jaffray analyst Gene Munster started shares of PayPal (PYPL) with an Underweight rating saying increased competition could pressure the stock's multiple over the next 6-24 months. Underweight is Piper's equivalent of a sell rating. Google's (GOOG) Android Pay and Apple's (AAPL) Apple Pay will give consumers a "real alternative to PayPal" for the first time, Munster tells investors in a research note. In addition, interest in payments from Amazon.com (AMZN) and Facebook (FB) bring potential for more digital wallet offerings, the analyst notes. Munster set a $30 price target for PayPal, which began trading yesterday following a spinoff from parent company eBay (EBAY). Shares of the online payment system closed Monday up $2.08 to $40.47.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use